Voriconazole
Voriconazole-13479
Voriconazole
13479
LAB13479
VOR
UK-109,496
Vfend
Vfend
Treatment of invasive aspergillosis, esophageal candidiasis, candidemia, candida deep tissue infections or serious fungal infections caused by Scedosporium apiospermum and fusarium
Serum
1.0 mL
0.5 mL
Do not use a gel barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage times, the decrease in drug level due to absorption may be clinically significant.
- Allow sample to clot
- Spin
- Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as serum, within two (2) hours of sample collection
EDTA plasma
Immediately after collection, mix tube thoroughly by gentle inversion, 8 - 10 times, to prevent clotting
- Spin
- Transfer plasma to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as EDTA plasma, within two (2) hours of sample collection
Refrigerated (preferred) - 14 days
Ambient - 14 days
Frozen - 14 days
- Gel barrier tubes
LabCorp Burlington (700353): R-LC
Mo - Fr
8 days
Liquid chromatography/tandem mass spectrometry (LC/MS-MS)
An interpretive report will be provided
Do not use a gel barrier tube.
The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage times, the decrease in drug level due to absorption may be clinically significant.
The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage times, the decrease in drug level due to absorption may be clinically significant.
80285
Result 38370-3
04/11/2019
04/06/2022
04/06/2022